Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...

Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...

Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...

Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Every parent should know and check for signs of leukemia. Because, checking and handling that is not fast and right can ...

Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...